Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma

• click to rate

  Posted by Two Blokes Jun 19 - Filed in Stock - 2 views
  
  The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.